ArticleJSES international2025
Safety of bioinductive bovine collagen implants for arthroscopic rotator cuff repair.
Article in JSES international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Collagen-Enriched Immunomodulatory Hydrogel for Tendon Regeneration.Gels (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bioinductive reconstituted type I bovine collagen implants for augmenting arthroscopic rotator cuff repair (ARCR) may improve the healing rate and thickness of repaired tendons. However, there are concerns regarding the inflammatory responses and foreign body reactions associated with the use of foreign substances. This study aimed to evaluate the safety of type I bovine collagen bioinductive implants in ARCR. Methods: A retrospective cohort study was conducted on 74 patients who underwent ARCR using the surface-holding method; 37 patients were treated with bioinductive collagen implants (R group) and 37 patients were treated without implants (N-R group). The participants underwent routine preoperative blood tests at 1 and 2 weeks postoperatively. Magnetic resonance imaging (MRI) was performed at 1 week and 6-8 weeks postoperatively. The safety of the implant was assessed using serum inflammatory responses, such as C-reactive protein (CRP) and white blood cell (WBC) counts, and the presence of effusions in the glenohumeral joints and subacromial bursa on MRI. In addition, the need for reoperation owing to infection or foreign body reactions was examined. Statistical analyses were performed using Mann-Whitney Results: CRP levels and WBC counts normalized within 2 weeks postoperatively in both the R and N-R groups, with no significant differences between the groups at any time point. Effusions in the glenohumeral joints and subacromial bursa were present in both groups and were not significantly different between the R and N-R groups at 1 and 6-8 weeks postoperatively. No reoperations due to infection or inflammatory responses were observed within 6 months postoperatively in either group. Conclusion: The use of reconstituted type I bovine collagen bioinductive implants in ARCR did not significantly affect postoperative inflammatory responses or increase the risk of effusion. The absence of reoperations due to clinical infections or foreign body reactions further supports the safety of the implants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.